Table 1 Baseline clinical characteristics, laboratory findings, and predisposing factors in the group of patients with sarcoidosis
Variable | No. of cases/No. of patients or range | (%) or average ± SD |
|---|---|---|
Gender | ||
Female | 13/31 | 41.9 |
Male | 18/31 | 58.1 |
Age (years) | 24–64 | 42.6 ± 13.0 |
Tobacco smoke | ||
Active | 9/31 | 29.0 |
Secondary | 20/31 | 64.5 |
Area of residence | ||
Rural | 15/31 | 48.4 |
Urban | 16/31 | 51.6 |
Healthy condition | ||
Shortness of breath, wheezing | 12/31 | 38.7 |
Cough | 16/31 | 51.6 |
Expectoration | 4/31 | 12.9 |
Fatigue: | 22/31 | 71.0 |
a short walk (n = 1) | 1/22 | 4.5 |
1st floor (n = 4) | 4/22 | 18.2 |
2nd floor (n = 17) | 17/22 | 77.3 |
Hypertension, coronary artery disease | 4/31 | 12.9 |
Allergy | 3/31 | 9.7 |
Asthma | 1/31 | 3.2 |
Recurrent infection (≥3/year) | 1/31 | 3.2 |
Recurrent infections in childhood | 8/31 | 25.8 |
Other (anaemia, celiac disease, thyroid disorders) | 8/31 | 25.8 |
Tuberculosis | 2/31 | 6.5 |
Laboratory findings | ||
FVC (ml) | 2740–6200 | 4208.1 ± 883.2 |
FEV1 (ml) | 1600–5050 | 3231 ± 810.3 |
FEV1/FVC% | 58–95 | 76.5 ± 8.7 |
pH | 7.35–7.49 | 7.43 ± 0.03 |
pO2 (mmHg) | 63.2–108 | 82.6 ± 10.5 |
pCO2 (mmHg) | 32.8–49.1 | 95.4 ± 2.7 |
Saturation (%) | 90.9–97.3 | 95.4 ± 1.8 |
IgG (g/l, reference: 7.0–16.0) | 7.1–21.6 | 10.8 ± 2.7 |
IgM (g/l, reference: 0.4–2.3) | 0.28–3.54 | 1.38 ± 0.8 |
IgA (g/l, reference: 0.7–4.0) | 0.51–6.9 | 2.57 ± 1.3 |
CRP (mg/l, reference: 0.0–5.0): | 0.51–80.48 | 7.23 ± 16.7 |
0.0–5.0 (n = 25) | 0.51–4.15 | 1.51 ± 0.93 |
5.1–80.48 (n = 6) | 5.8–80.48 | 31.10 ± 28.83 |
Changes in CT scan | 30/30 | 100 |
Changes in X-ray | 19/20 | 95 |
Changes observed during bronchofiberoscopy | 14/17 | 82.4 |